Navigation Links
New genetic clues for schizophrenia
Date:7/10/2011

This release is available in French.

De novo mutations genetic errors that are present in patients but not in their parents are more frequent in schizophrenic patients than in normal individuals, according to an international group of scientists led by Dr. Guy A. Rouleau of the University of Montreal and CHU Sainte-Justine Hospital. The discovery, published today in Nature Genetics, may enable researchers to define how the disease results from these mutations and eventually develop new treatments for it.

"The occurrence of de novo mutations, as observed in this study, may in part explain the high worldwide incidence of schizophrenia," says Dr. Rouleau, who is also Director of the CHU Sainte-Justine Research Center and researcher at the University of Montreal Hospital Research Centre. "Because the mutations are located in many different genes, we can now start to establish genetic networks that would define how these gene mutations predispose to schizophrenia," adds Simon Girard, the student who performed the key experiments that led to this discovery. "Most of the genes identified in this study have not been previously linked to schizophrenia, thereby providing new potential therapeutic targets."

Schizophrenia is a major mental disorder characterized by a wide spectrum of symptoms, including delusions, hallucinations, disturbances in thinking, and deterioration of social behaviours. According to the World Health Organization, as many as 24 million individuals worldwide suffer from schizophrenia and over half of them are not receiving appropriate care to relieve their symptoms.

Dr. Rouleau's team used modern DNA sequencing technologies to identify genetic changes in patients with schizophrenia whose parents showed no signs of the disease. To identify genetic mutations associated with schizophrenia, Dr. Rouleau and his team analysed approximately 20,000 genes from each participant in the study. The research team was especially interested in "de novo" mutations, meaning those that are present in patients but absent in their parents.

"Our results not only open the door to a better understanding of schizophrenia," adds Dr. Rouleau. "They also give us valuable information about the molecular mechanisms involved in human brain development and function."

The identification of de novo mutations in schizophrenia supports the hypothesis proposed by Dr. Rouleau in 2006, that this type of mutation plays a role in several diseases affecting brain development such as autism, schizophrenia and mental retardation.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-566-3813
University of Montreal
Source:Eurekalert

Related biology news :

1. Rare genetic disorder gives clues to autism, epilepsy, mental retardation
2. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
3. Study finds genetic variant plays role in cleft lip
4. Genetic finding implicates innate immune system in major cause of blindness
5. American College of Medical Genetics receives $13.5M NIH contract
6. Clue to genetic cause of fatal birth defect
7. Can genetic information be controlled by light?
8. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
9. Modern genetics vs. ancient frog-killing fungus
10. Genetic based human diseases are an ancient evolutionary legacy
11. Genetic evidence for avian influenza movement from Asia to North America via wild birds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at Trinity ... for graphene by combining the material with Silly ... sensitive pressure detector able to sense pulse, blood ... small spider.  The research team,s ... be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral ... which grew to over 40 granted and pending patents. ... , , The Company,s ... " System, Device, and Method Estimating Force Applied to a Touch ... forego costly hardware components needed to estimate the force and pressure applied ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... Jan. 23, 2017   Enteris BioPharma, Inc. , ... with Sanofi to leverage Enteris, proprietary and ... to develop an oral formulation of one of Sanofi,s ... , Chief Executive Officer and Executive Chairman of Enteris ... of the tremendous value our Peptelligence platform program offers ...
(Date:1/23/2017)... Atlas Genetics Ltd., the ultra-rapid Point-Of-Care ... D financing, raising $35 million from a syndicate including all ... ... the Atlas Genetics io┬« system has been completed with the ... in February 2016.  This new Series D equity issue will ...
(Date:1/23/2017)... Jan. 23, 2017  Alkahest Inc. ("Alkahest"), a ... neurodegenerative diseases and other age-related conditions, announced today ... as Chief Medical Officer. In this role, Dr. ... activities at Alkahest and serve on the Executive ... served as Executive Director at Dynavax, where he ...
(Date:1/23/2017)... ... January 23, 2017 , ... CallTower is proud ... TELEPHONY Product of the Year Award winner for 2017. , For three consecutive ... communications solutions. In 2016, CallTower was awarded with the hosted VoIP Excellence award and ...
Breaking Biology Technology: